Emmanuel S Antonarakis
Overview
Explore the profile of Emmanuel S Antonarakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
408
Citations
14344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hage Chehade C, Ozay Z, Ostrowski M, Mercinelli C, Gebrael G, Sayegh N, et al.
Eur Urol
. 2025 Mar;
PMID: 40074645
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel...
2.
Ghirardelli Smith O, Tsai A, Zhong M, Dejban P, Nelson A, Dolan M, et al.
Front Oncol
. 2025 Mar;
15:1547258.
PMID: 40071092
Introduction: We report for the first time a case of a postpubertal patient presenting with a metastatic prepubertal-type testicular teratoma. Case Discussion: A 29-year-old male with a history of corrected...
3.
Arafa A, Yadav S, Marshall C, Mauer E, Huang M, Yilma B, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 40019487
Background: Germline alterations in homologous recombination repair (gHRR) genes impact the pathogenesis, treatment options, and survival of cancer patients. However, distinct gHRR gene alterations may differentially impact treatment response and...
4.
Raychaudhuri R, Tuchayi A, Low S, Arafa A, Graham L, Gulati R, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39920014
Background And Objective: The prostate-specific membrane antigen (PSMA) radioligand Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors (PARPi) are approved for patients with mCRPC...
5.
Pitzen S, Rudenick A, Qiu Y, Zhang W, Munro S, McCluskey B, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(6):e2415308122.
PMID: 39913208
Inhibiting the androgen receptor (AR) is effective for treatment of advanced prostate cancers because of their AR-dependent luminal epithelial cell identity. Tumors progress during therapy to castration-resistant prostate cancer (CRPC)...
6.
Lozada J, Elliott A, Evans M, Wacker J, Storey K, Egusa E, et al.
Cancer Res Commun
. 2025 Jan;
5(2):318-326.
PMID: 39874041
DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological...
7.
Marshall C, Antonarakis E, Patnaik M
Blood Rev
. 2025 Jan;
70:101269.
PMID: 39864960
While radiotherapeutics have demonstrated significant clinical benefit across multiple cancer types including thyroid cancer, neuroendocrine tumors, and prostate cancer, hematological toxicities can be frequent and challenging. It remains unknown to...
8.
Turesky R, Jones C, Guo J, Cammerrer K, Maertens L, Antonarakis E, et al.
Toxics
. 2025 Jan;
13(1).
PMID: 39853040
Heterocyclic aromatic amines (HAAs), formed during the cooking of meat, are potential human carcinogens, underscoring the need for long-lived biomarkers to assess exposure and cancer risk. Frequent consumption of well-done...
9.
Arafa A, Ludwig M, Tuncer O, Kollitz L, Gustafson A, Boytim E, et al.
Cancers (Basel)
. 2025 Jan;
16(24).
PMID: 39766159
: Prostate cancer treatment has been revolutionized by targeted therapies, including PARP inhibitors, checkpoint immunotherapies, and PSMA-targeted radiotherapies. Despite such advancements, accurate patient stratification remains a challenge, with current methods...
10.
Hwang J, Likasitwatanakul P, Deshmukh S, Wu S, Kwon J, Toye E, et al.
Clin Cancer Res
. 2025 Jan;
31(5):936-948.
PMID: 39745364
Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain...